Novartis says positive interim results on rare kidney disease drug, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

IgAN is a rare autoimmune disease mostly affecting young adults, which can lead to kidney failure. The study is to continue for a further 15 months. In total, it will cover around 450 adult patients with primary IgAN who are at high risk of progressing to kidney failure., IgAN is a rare autoimmune disease mostly affecting young adults, which can lead to kidney failure. The study is to continue for a further 15 months. In total, it will cover around 450 adult patients with primary IgAN who are at high risk of progressing to kidney failure., , Read More

Leave a Reply

Your email address will not be published. Required fields are marked *